Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Burlington Stores Inc (BURL) vs ResMed Inc. (RMD) Price & Performance

Burlington Stores IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Burlington Stores Inc vs ResMed Inc. — how do they compare? Burlington Stores Inc trades at $351.97 (market cap $22.59B), while ResMed Inc. trades at $225.55 (market cap $32.61B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.

BURLRMD
Market Cap
$22.59B$32.61B
Sector
Consumer CyclicalHealth
52-Week High
$372.19$293.73
52-Week Low
$242.43$182.82
Enterprise Value
$27.71B$31.97B
Dividend Yield
1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Burlington Stores Inc

Burlington Stores (BURL) trades at $353.4, down 4.87% over 24 hours but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding expectations. Revenue grew to $10.63 billion in 2025, and the smaller-store strategy is boosting sales productivity. Analyst consensus is overwhelmingly positive, with 94% buy ratings and a $367 price target.

Outlook remains favorable due to consistent earnings outperformance and growth initiatives, though risks include high valuation multiples and competitive retail pressures. The stock offers upside potential aligned with analyst targets, but investors should monitor execution on expansion and margin sustainability.

ResMed Inc.

ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.

The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.

Returns comparison

Trailing returns across standard periods

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD